Reckitt Benckiser Group agreed to pay $1.4 billion to settle a U.S. investigation into the sales and marketing of Suboxone Film, a product managed by the spinout company Indivior.
Less than a month after filing for bankruptcy, Insys Therapeutics gained a reprieve from some lawsuits as well as a path forward for regulatory approval of an opioid overdose treatment.
After accusations of being influenced by Purdue Pharma, the World Health Organization (WHO) withdrew two guidelines for opioid medications following criticism from U.S. lawmakers.
U.S. drugmakers filed a lawsuit challenging a new government regulation that would require them to disclose the list price of prescription drugs in direct-to-consumer television advertisements.
Mallinckrodt Plc tentatively agreed to pay $15.4 million to resolve a U.S. Justice Department probe into how a drugmaker that the company now owns marketed an expensive treatment for a rare infant seizure disorder and multiple sclerosis.
Vaunted immunotherapy pioneers from the Dana-Farber Cancer Institute won a key court case that could be worth billions of dollars.
Gilead Sciences has been accused of withholding safer formulations of its HIV drugs in order to maximize profits on those medications that had already been approved, such as Truvada.
Five U.S. states filed lawsuits accusing Purdue Pharma LP of illegally marketing and selling opioids, including OxyContin.
Teva and Novartis’ Sandoz are contesting charges stemming from a multi-state lawsuit alleging that a number of generic drugmakers conspired to manipulate prices on more than 100 drugs.
U.S. states filed a lawsuit accusing Teva Pharmaceuticals USA Inc. of orchestrating a sweeping scheme with 19 other drug companies to inflate drug prices – sometimes by more than 1,000 percent – and stifle competition for generic drugs, state prosecutors said.